Page last updated: 2024-12-10

prostaglandin f2beta

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

prostaglandin F2beta: RN given refers to (5Z,9 beta,11 alpha,13E,15S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

prostaglandin F2beta : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is the 9beta-hydroxy epimer of prostaglandin F2alpha. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280506
CHEMBL ID1894513
CHEBI ID28922
SCHEMBL ID3364356
MeSH IDM0112321

Synonyms (58)

Synonym
prostaglandin f2-beta
CHEBI:28922 ,
(5z,13e,15s)-9beta,11alpha,15-trihydroxyprosta-5,13-dien-1-oic acid
BSPBIO_001493
5-heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-, stereoisomer
pgf(sub 2-beta)
pgf2-beta
prostaglandin f(sub 2-beta)
prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5z,9-beta,11-alpha,13e,15s)-
IDI1_033963
9r,11r,15s-trihydroxy-5z,13e-prostadienoic acid
LMFA03010025
PDSP1_000079
prostaglandin f2b
9beta,11alpha-pgf2alpha
pgf2beta
5-heptenoic acid, 7-[3,5-dihydroxy-2(3-hydroxy-1-octenyl)cyclopentyl]-, stereoisomer
C02314
prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-,(5z,9beta,11alpha,13e,15s)-
9beta,11alpha-pgf2a
4510-16-1
prostaglandin f2beta
pgf2b
NCGC00161292-01
NCGC00161292-02
NCGC00161292-04
NCGC00161292-03
HMS1989K15
9b,11a prostaglandin f2
BML1-G05
HMS1361K15
HMS1791K15
SCHEMBL3364356
(z)-7-[(1r,2r,3r,5r)-3,5-dihydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
9beta,11alpha-prostaglandin f2
CHEMBL1894513
prostaglandin f2.beta.
prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-, (5z,9.beta.,11.alpha.,13e,15s)-
HMS3648B14
HMS3402K15
9b,11a-pgf2
(5z,13e)-9,11,15-trihydroxy-prosta-5,13-dien-1-oic acid
7-[3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid stereoisomer
(5z,13e)-9,11,15-trihydroxy-prosta-5,13-dien-1-oate
7-[3a,5b-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoate
7-[3,5-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoate
Q27103967
7-[3a,5b-dihydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl]-5-heptenoic acid
SR-01000946478-1
sr-01000946478
benzoxoniumchloride
prostaglandin f2 beta
DTXSID40859478
9 beta ,11 alpha -prostaglandin f2
9beta-pgf2alpha
prostaglandin f2beta lipid maps(r) ms standard
prostaglandin f2??
AKOS040755380
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins Fbeta
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency0.00670.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (50.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.14 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]